Comparing Two Injectable Forms of Cagrilintide With Placebo in Overweight or Obesity
Compares two injectable versions of cagrilintide with placebo in adults with overweight or obesity.
Key facts
- Who runs it
- Novo Nordisk A/S
- Where
- Conyers, Greensboro, Honolulu, Indianapolis, Lexington, Newport News, North Charleston, Oak Park, Richmond, Wilmington, and Winchester, United StatesSee the 11 sitesAlso in 5 other countries, 25 sites
- Trial code
- NCT07745504
- EU 2025-524249-29-00
- U1111-1328-5168
- Registry title
- A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 285 people, planned
- Started
- 4 Aug 2026
- Expected to end
- 6 Jul 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cagrilintide
- Placebo cagrilintide
- Placebo semaglutide
- Record updated
- 4 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with overweight or obesity to test two versions of the injectable medicine cagrilintide against placebo for weight loss.
- Age
- 18 years or older
- Sex
- All sexes can join (sex assigned at birth, all gender identities)
- Disease stage
- Body mass index (BMI) of 30.0 kg/m^2 or more, or BMI of 27.0 kg/m^2 or more with at least one weight-related health problem, such as high blood pressure, abnormal blood fats, sleep apnoea or heart disease.
- Earlier treatment
- People who took any weight-management medicine within 180 days before screening, or plan to start one, cannot join. People who took amylin-based compounds before cannot join.
Main reasons for not taking part
- History of type 1 or type 2 diabetes
- Previous dosing of marketed or non-marketed amylin-based compounds
- Treatment, or plan to start treatment, with a weight-management medicine within 180 days before screening
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
- Male or female (sex assigned at birth, inclusive of all gender identities)
- Age 18 years or above at the time of signing the informed consent
- Body mass index (BMI) greater than or equal to (>=) 30.0 kilograms per square meter (kg/m\^2), or BMI >= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
Who cannot take part
- Previous dosing of marketed or non-marketed amylin-based compounds
- Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening
- History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D)
Where in United States
Also in 5 other countries, 25 sites
- Hope Clin Res & WellnessConyers, United StatesContact: Novo NordiskTaking people
- PharmQuestGreensboro, United StatesContact: Novo NordiskTaking people
- East West Med Res InstHonolulu, United StatesContact: Novo NordiskTaking people
- Midwest Inst For Clin ResIndianapolis, United StatesContact: Novo NordiskTaking people
- The Alliance for Multispecialty Research LLC AMRLexington, United StatesContact: Novo NordiskTaking people
- Health Res of Hampton RoadsNewport News, United StatesContact: Novo NordiskTaking people
- Coastal Carolina Res CtrNorth Charleston, United StatesContact: Novo NordiskTaking people
- Walgreens - Store 11760Oak Park, United StatesContact: Novo NordiskNot yet recruiting
- National Clin Res Inc.Richmond, United StatesContact: Novo NordiskTaking people
- KDCILM, LLC & Accellacare US, Inc.Wilmington, United StatesContact: Novo NordiskTaking people
- Selma Medical AssociatesWinchester, United StatesContact: Novo NordiskTaking people
About the trial
What the trial wants to find out
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.
The 3 groups in the trial
- Cagrilintide + placebo semaglutide in device 1 and placebo cagrilintide in device 2Treatment being tested
Participants will receive cagrilintide along with placebo matched to semaglutide in device 1 and placebo matched to cagrilintide in device 2 subcutaneously (s.c) once weekly for 26 weeks.
Treatment: Cagrilintide, Placebo cagrilintide, and Placebo semaglutide
- Cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1Treatment being tested
Participants will receive cagrilintide in device 2 and placebo matched to cagrilintide along with placebo matched to semaglutide in device 1 s.c once weekly for 26 weeks.
Treatment: Cagrilintide, Placebo cagrilintide, and Placebo semaglutide
- Placebo cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1Placebo, for comparison
Participants will receive placebo matched to cagrilintide in device 2 and placebo matched to cagrilintide along with placebo matched to semaglutide in device 1 s.c once weekly for 26 weeks.
Treatment: Placebo cagrilintide and Placebo semaglutide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity
- Plain-language title
- Comparing Two Injectable Forms of Cagrilintide With Placebo in Overweight or ObesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 September 2026